Categories: News

Genmed posts revenues of £38.6 million demonstrating continued uptake of vendor neutral managed services in the NHS

Genmed posts revenues of £38.6 million demonstrating continued uptake of vendor neutral managed services in the NHSGenmed posts revenues of £38.6 million demonstrating continued uptake of vendor neutral managed services in the NHS
FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
November 23, 2018 – Genmed, a specialist provider of vendor neutral managed services to the NHS, today announces continued strong business performance for its financial year ending March 31, 2018. Business highlights Revenues increased 19% year on year from £32.4 million to £38.6 million with EBITDA of £240,000 – profits a reflection of the increased investment in the business from a staff, systems and infrastructure perspective. Since 2014, Genmed’s revenues have grown 275% demonstrating the…

Source: RealWire

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
AddThis Website Tools
user

Share
Published by
user
6 years ago

Recent Posts

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…

21 hours ago

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine…

21 hours ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…

21 hours ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…

21 hours ago

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity –…

21 hours ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…

21 hours ago